New York State Common Retirement Fund Has $6.40 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

New York State Common Retirement Fund boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,563 shares of the biopharmaceutical company's stock after purchasing an additional 5,162 shares during the quarter. New York State Common Retirement Fund owned approximately 0.07% of Intra-Cellular Therapies worth $6,395,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. True Wealth Design LLC purchased a new position in Intra-Cellular Therapies during the 3rd quarter valued at about $32,000. GAMMA Investing LLC increased its stake in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of Intra-Cellular Therapies in the 3rd quarter worth approximately $74,000. Venturi Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies in the 4th quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Intra-Cellular Therapies during the 3rd quarter valued at approximately $97,000. Hedge funds and other institutional investors own 92.33% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ITCI. Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. Piper Sandler reissued a "neutral" rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Mizuho downgraded Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and lowered their price target for the company from $140.00 to $132.00 in a report on Monday, February 24th. Finally, JPMorgan Chase & Co. lifted their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an "overweight" rating in a report on Monday, November 4th. Ten investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $106.08.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ ITCI traded down $0.05 during mid-day trading on Friday, hitting $128.20. 1,486,294 shares of the company's stock traded hands, compared to its average volume of 3,849,049. The company's 50-day moving average is $114.58 and its two-hundred day moving average is $91.61. Intra-Cellular Therapies, Inc. has a 1 year low of $63.30 and a 1 year high of $129.00. The company has a market capitalization of $13.63 billion, a P/E ratio of -147.35 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Insider Activity at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the business's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares of the company's stock, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.60% of the stock is owned by corporate insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.